3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
218
Rectal Neoplasms
133
Stomach Neoplasms
111
Colonic Neoplasms
101
Pancreatic Neoplasms
81
Neoplasm Metastasis
57
Esophageal Neoplasms
48
Neoplasms
31
Adenocarcinoma Of Esophagus
23
Adenocarcinoma
21
Carcinoma, Hepatocellular
20
Carcinoma, Non-Small-Cell Lung
16
Biliary Tract Neoplasms
16
Gallbladder Neoplasms
15
Cholangiocarcinoma
15
Gastrointestinal Neoplasms
14
Liver Neoplasms
13
Lymphoma, Large B-Cell, Diffuse
12
Breast Neoplasms
12
Unspecified Adult Solid Tumor, Protocol Specific
11
Esophageal Squamous Cell Carcinoma
11
Bile Duct Neoplasms
10
Recurrence
9
Peritoneal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Ovarian Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Appendiceal Neoplasms
5
Advanced Gastric Cancer
5
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Spinocerebellar Degenerations
×
Oxaliplatin
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts